Clinical Trials

2 studies in Renal Dysfunction

1. Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Scottsdale and Phoenix, AZ View Summary
   Close

   Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

   Location:

   Scottsdale and Phoenix, AZ

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Ifetroban sodium (ifetroban) is an investigational drug that has been studied previously in healthy volunteers and patients with cardiovascular diseases. Cumberland Pharmaceuticals Inc. (CPI) is developing ifetroban for treatment of type 1 and type 2 hepatorenal syndrome (HRS) and proposed to conduct a study in hospitalized adult patients with HRS to assess the safety and pharmacokinetics of escalating doses of ifetroban. The primary objective of this study is as follows: - To determine the pharmacokinetic profile of multiple daily intravenous doses of ifetroban and its major metabolite ifetroban acylglucuronide. - To determine the tolerability and safety of ifetroban injection in patients with HRS. The secondary objective of this study is as follows: • To determine if ifetroban changes renal function, showing evidence of HRS reversal.

   NCT ID:

   NCT01436500

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   
   Scottsdale: Jennifer McGrew, RN, BSN 480-342-2479
                       
   
   

2. Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function Rochester, MN View Summary
   Close

   Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway. The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and renal dysfunction will improve renal function with increased sodium excretion, glomerular filtration rate and effective renal plasma flow and renal function reserve as compared to the response of placebo-treated subjects.

   NCT ID:

   NCT01678794

   IRB Number:

   09-003284

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Lynn Harstad 507-284-4838